US 10,889,631 B2
Therapeutic variant alpha-2-macroglobulin compositions
Lewis Hanna, Naples, FL (US); John David Laughlin, Jupiter, FL (US); and Shawn Robert Browning, Jupiter, FL (US)
Assigned to Cytonics Corporation, Jupiter, FL (US)
Filed by CYTONICS CORPORATION, Jupiter, FL (US)
Filed on Jul. 17, 2019, as Appl. No. 16/514,591.
Application 16/514,591 is a division of application No. 15/528,387, granted, now 10,400,028, previously published as PCT/US2015/061852, filed on Nov. 20, 2015.
Claims priority of provisional application 62/082,304, filed on Nov. 20, 2014.
Prior Publication US 2019/0359690 A1, Nov. 28, 2019
Prior Publication US 2020/0148748 A9, May 14, 2020
Int. Cl. C07K 14/81 (2006.01); A61K 45/06 (2006.01); C12Q 1/37 (2006.01); C12P 19/34 (2006.01); A61K 38/57 (2006.01); A61K 9/00 (2006.01)
CPC C07K 14/811 (2013.01) [A61K 9/0019 (2013.01); A61K 38/57 (2013.01); A61K 45/06 (2013.01); C12P 19/34 (2013.01); C12Q 1/37 (2013.01); G01N 2333/811 (2013.01); G01N 2500/04 (2013.01); G01N 2500/20 (2013.01)] 20 Claims
 
1. A method of treating a mammalian subject with an inflammatory disease or condition, comprising administering to the subject a pharmaceutical composition comprising
(a) a pharmaceutically effective amount of a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence with at least 80% identity to SEQ ID NO: 20; and
(b) a pharmaceutically acceptable carrier.